Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Harvard Business School
Teva
UBS
Merck

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,372,968

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,372,968
Title:RNA interference mediating small RNA molecules
Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
Inventor(s): Tuschl; Thomas (New York, NY), Elbashir; Sayda Mahgoub (Cambridge, MA), Lendeckel; Winfried (Hohengandern, DE)
Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V. (Munich, DE) Massachusetts Institute of Technology (Cambridge, MA) Whitehead Institute for Biomedical Research (Cambridge, MA) University of Massachusetts (Boston, MA)
Application Number:12/537,602
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,372,968
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,372,968

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alnylam Pharms Inc ONPATTRO patisiran sodium SOLUTION;INTRAVENOUS 210922-001 Aug 10, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,372,968

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
00126325Dec 1, 2000

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
Colorcon
QuintilesIMS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.